The COVID-19 public health emergency disrupted access to in-person behavioral health treatment beginning in the spring of 2020. This prompted federal telehealth flexibilities that have permitted the initiation of controlled medications, including prescription stimulants for attention-deficit/hyperactivity disorder, via telehealth and without an in-person medical evaluation. In a national sample of child and adult Medicaid and Children’s Health Insurance Program (CHIP) enrollees, we found that…
